Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer With Bone Metastases
Anticancer Research · 2024
DOI: 10.21873/anticanres.17278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Yohei Asano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Bone Neoplasms, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: The aim of the study was to develop a novel predictive scoring system based on the dynamics of serum inflammatory indicators in immune checkpoint inhibitor (ICI) treatment on non-small-cell lung cancer (NSCLC) with bone metastases. PATIENTS AND METHODS: Sixty patients with NSCLC and bone metastases treated with ICIs between January 2016 and March 2021 were included in the development cohort. Serum neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP) levels were assessed before (pre-value) and 6 weeks after (post-value) ICI treatment, and a novel predictive score was developed: pre-value ≥ post-value, 0 points; pre-value < post-value, 1 point; total score: 0-2 points. The associations of these dynamics and the score with clinical outcomes, including overall survival (OS), progression-free survival (PFS), response rate (RR) of bone metastases, and disease control rate (DCR), were evaluated. Furthermore, cross-validation was performed with 23 patients after April 2021 using the same inclusion criteria. RESULTS: The patients with decreased serum inflammation levels had significantly better OS, PFS, and RR than those with increased levels. Applying the developed score to the development cohort, the patients with 0 points had significantly better OS, PFS, and RR than others. In multivariable analysis, the score independently predicted treatment response to ICI for bone metastasis and prognosis. Cross-validation showed that OS, PFS, and RR were significantly better in the patients in the 0-point group. CONCLUSION: The early NLR and CRP dynamics were associated with therapeutic responses to ICIs in NSCLC with bone metastases. Our novel scoring system based on these dynamics is simple and has a high predictive accuracy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
- Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan; norinori-ya@wing.ocn.ne.jp.
- Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
- Department of Thoracic Surgery, Kanazawa University Hospital, Kanazawa, Japan.
- Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Zitieren
APA
Asano, Y., Yamamoto, N., Hayashi, K., Takeuchi, A., Kato, S., Miwa, S., Okuda, M., Matsumoto, I., Yano, S., & Demura, S. (2024). Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer With Bone Metastases. Anticancer Research. https://doi.org/10.21873/anticanres.17278
Vancouver
Asano Y, Yamamoto N, Hayashi K, Takeuchi A, Kato S, Miwa S, et al. Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer With Bone Metastases. Anticancer Research. 2024. doi:10.21873/anticanres.17278
BibTeX
@article{Asano2024,
author = {Asano, Yohei and Yamamoto, Norio and Hayashi, Katsuhiro and Takeuchi, Akihiko and Kato, Satoshi and Miwa, Shinji and Okuda, Miho and Matsumoto, Isao and Yano, Seiji and Demura, Satoru},
title = {Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer With Bone Metastases},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17278}
}
EUVIMED